We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Neuromyelitis Optica Spectrum Disorder: Therapeutic Innovations and Complex Decision-Making.
- Authors
Hartung, Hans‐Peter; Hartung, Hans-Peter
- Abstract
Ninety-six percent of eculizumab-treated patients and 72 to 78% of satralizumab treated patients were relapse-free at 96 weeks in the respective trials. To exclude pseudorelapses, after enrollment of 88 participants, the protocol was changed and required retrospective and prospective evaluation of relapses by a relapse adjudication committee. We do not know presently how many patients in the aquaporin-4 IgG-seronegative groups harbored antibodies to myelin oligodendrocyte glycoprotein (MOG) and may belong to the emerging MOG-antibody associated disease category.11,12 In aquaporin-4 IgG-negative patients, one may therefore be left to off-label use of immunosuppressants. The median time to first relapse was 103 weeks for the placebo group but could not be established in the eculizumab group because of insufficient numbers of relapses.
- Subjects
NEUROMYELITIS optica; MAGNETIC resonance imaging; PHYSICIANS; AUTOANTIBODIES
- Publication
Annals of Neurology, 2021, Vol 89, Issue 6, p1084
- ISSN
0364-5134
- Publication type
journal article
- DOI
10.1002/ana.26087